

Review Form 3

Journal Name:	Asian Journal of Medicine and Health
Manuscript Number:	Ms_AJMAH_127796
Title of the Manuscript:	INTEGRATING SGLT-2 INHIBITORS INTO THE CLINICAL MANAGEMENT OF TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: CURRENT EVIDENCE AND FUTURE OUTLOOK
Type of the Article	Original Research Article

PART 1: Comments

	Reviewer's comment	Author's Feedback <i>(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.	The manuscript addresses a crucial topic in clinical medicine by evaluating the integration of SGLT-2 inhibitors into the management of Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD). SGLT-2 inhibitors have emerged as a significant advancement, not only in glycemic control but also in providing cardiovascular and renal protective effects, which are critical in high-risk populations. This article provides a comprehensive synthesis of evidence from landmark trials, making it valuable for guiding clinical decision-making and policy formulation in diabetes care.	
Is the title of the article suitable? (If not please suggest an alternative title)	The title is suitable as it clearly reflects the scope and focus of the study. No changes suggested.	
Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here.	The abstract is comprehensive, providing a clear summary of the objectives, methods, results, and implications. However, adding specific quantitative outcomes (e.g., reduction percentages or hazard ratios) could enhance clarity and impact.	
Is the manuscript scientifically, correct? Please write here.	The manuscript is scientifically robust and well-referenced. All major points are substantiated with findings from reputable clinical trials and meta-analyses.	
Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.	The references are sufficient and recent, covering major studies like EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, CREDENCE, DAPA-CKD, and EMPA-KIDNEY. Suggest including a recent meta-analysis or systematic review (if available) on SGLT-2 inhibitors for broader validation.	
Is the language/English quality of the article suitable for scholarly communications?	The language is clear, concise, and suitable for scholarly communication. Minor grammatical corrections might enhance readability.	
Optional/General comments	<p>Consider adding a brief section on the cost-effectiveness or accessibility of SGLT-2 inhibitors in low- and middle-income countries for practical relevance.</p> <p>Strengths: Comprehensive coverage, robust methodology, and clinical relevance. Suggestions for improvement: Incorporate quantitative outcomes in the abstract and consider addressing economic implications</p> <p>No ethical concerns identified as the manuscript is a narrative review based on published data. None identified. Authors have disclosed the use of non-generative AI in manuscript preparation. No evidence of plagiarism detected in the manuscript</p>	

Review Form 3

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Ishankumar Gupta
Department, University & Country	MUHS, India